NeuroOne Medical Technologies (NMTC)
Develops thin-film electrode and ablation systems for neurological diagnosis and treatment.
$1.39
After-hours close+0.02 (+1.45%)
At close$1.37(+5.39%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Sep 2023 | Q1 FY24Dec 2023 | Q2 FY24Mar 2024 | Q3 FY24Jun 2024 | Q4 FY24Sep 2024 | Q1 FY25Dec 2024 | Q2 FY25Mar 2025 | Q3 FY25Jun 2025 | Q4 FY25Sep 2025 | Q1 FY26Dec 2025 | Q2 FY26Mar 2026 | Q3 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 1 | 1 | 0 | 3 | 1 | 2 | 3 | 3 | 2 | 2 |
| Cost of revenue | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 2 | 2 | 1 | 1 |
| 3 | 4 | 3 | 3 | 3 | 0 | 3 | 3 | 3 | 3 | 3 | 4 | |
| Research & development | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 0 | 0 | 2 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | −3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −3 | −3 | −3 | −3 | −3 | 2 | −3 | −2 | −1 | −2 | −2 | −2 |
| 0 | 0 | 0 | 0 | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −3 | −3 | −3 | −3 | −3 | 2 | −2 | −2 | −2 | −1 | −2 | −2 |
| Net income from continuing operations | −3 | −3 | −3 | −3 | −3 | 2 | −2 | −2 | −2 | −1 | −2 | −2 |
| Net income | −3 | −3 | −3 | −3 | −3 | 2 | −2 | −2 | −2 | −1 | −2 | −2 |
| EPS, basic | −$0.78 | −$0.84 | −$0.66 | −$0.60 | $2.04 | $0.35 | −$0.44 | −$0.19 | −$0.26 | −$0.17 | −$0.25 | −$0.23 |
| EPS, diluted | −$0.78 | −$0.84 | −$0.66 | −$0.60 | $2.04 | $0.35 | −$0.44 | −$0.19 | −$0.26 | −$0.17 | −$0.25 | −$0.23 |
| Weighted average shares, basic | 4 | 4 | 4 | 5 | 4 | 5 | 5 | 8 | 7 | 8 | 8 | 9 |
| Weighted average shares, diluted | 4 | 4 | 4 | 5 | 4 | 5 | 5 | 8 | 7 | 8 | 9 | 9 |
| EBITDA | −3 | −3 | −3 | −3 | −3 | 2 | −2 | −1 | −2 | −1 | −2 | −2 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −3 | −3 | −3 | −3 | −3 | 2 | −2 | −1 | −2 | −1 | −2 | −2 |
